Transient ischemic attack after mRNA-based COVID-19 vaccination during pregnancy: A case report

Table 1 Summary of laboratory results for this patient

Laboratory studies	Results (reference value)
Polymerase chain reaction test for SARS-CoV-2 virus using a nasopharyngeal swab	Undetectable
Platelet count nadir, × 103 cells/μL	185 (150-400)
D-dimer peak, ng/mL	5351.22 (0-499)
Activated partial thromboplastin time peak, s	26.5 (23.9-35.5)
Prothrombin time, s	10.3 (8-12)
Anticardiolipin antibody level	4.69 ± 1.29
IgG, GPL	< 1.6 (0-19.9)
IgM, MPL	4.9 (0-12.5)
B2-glycoprotein 1 class
IgG, SGU	< 1.4 (0-19.9)
IgM, SMU	0.9 (0-20)
Antinuclear antibodies
Homogeneous, speckled, centromere, nucleolar, granular	< 1:40 (1:40)
Anti-thyroglobulin antibodies, IU/mL	< 0.9 (0-4)
Anti-thyroid peroxidase antibodies, IU/mL	< 0.25 (0-9)
Total cholesterol, mg/dL	309 (0-200)
Triglyceride, mg/dL	476 (0-150)
Low-density lipoprotein cholesterol, mg/dL	197 (0-100)
Glycated hemoglobin A1C, %	5.1 (4-6)
Magnetic resonance imaging of the brain	No signs of ischemic stroke
Magnetic resonance angiography of the neck	No stenosis (> 90%) of both extracranial ICAs and CCAs
Transesophageal echocardiography	No thrombus formation, no notable vegetations, and no pathological shunt

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; GPL: IgG phospholipid units; MPL: IgM phospholipid units; SGU: Standard IgG units; SMU: Standard IgM units; ICAs: Internal carotid arteries; CCAs: Common carotid arteries.